Method and apparatus for treating vulnerable coronary plaques using drug-eluting stents
A drug-eluting intravascular stent comprising an anti-restenosis agent covered by a biodegradable coating, and a method for treating vulnerable plaque in coronary vessels using said stent is disclosed. The biodegradable layer covers at least a portion of the drug-eluting layer of the stent, and is adapted to slowly erode over a preset period of time, preventing the release of therapeutic amounts of the anti-restenosis agent from the drug-eluting layer during the preset period. By delaying the release of the anti-restenosis agent, a thin layer of neointima will grow during the preset period. This tissue growth is sufficient to encapsulate the stent and cover the vulnerable plaque, but not significant enough to cause harmful restenosis or occlusion of the vessel. Once the biodegradable coating is eroded, the anti-restenosis agent begins release from the drug-eluting layer, and the progression of neointimal hyperplasia ceases.
1 ) A method for treating vulnerable plaque in a vessel, the method comprising the steps of:
a) identifying the location of the vulnerable plaque in the vessel;
b) delivering a drug-eluting intravascular stent comprising a tubular configuration of structural members to the location of the vulnerable plaque, the intravascular stent comprising a drug-eluting layer coated over at least a portion of the intravascular stent structural members, the drug-eluting layer comprising an anti-restenosis agent; and a biodegradable layer covering at least a portion of the drug-eluting layer, the biodegradable layer being adapted to slowly erode over a preset period of time, the biodegradable layer also being adapted to prevent release of therapeutic amounts of the anti-restenosis agent from the drug-eluting layer during the preset period of time;
c) deploying the intravascular stent into the wall of the vessel over the location of the vulnerable plaque; and
d) causing therapeutic amounts of the anti-restenosis agent to elute from the drug-eluting layer into the location of the vulnerable plaque after the preset period of time.
2 ) The method of claim 1 wherein the anti-restenosis agent comprises sirolimus.
3 ) The method of claim 1 wherein the biodegradable layer contains an anti-thrombogenic agent.
4 ) The method of claim 3 wherein the anti-thrombogenic agent is heparin.
5 ) The method of claim 1 wherein the biodegradable layer contains an anti-platelet agent.
6 ) The method of claim 5 wherein the anti-platelet agent is ReoPro.
7 ) The method of claim 1 wherein the drug-eluting layer comprises a lipid lowering agent.
8 ) The method of claim 1 wherein the drug-eluting layer comprises a statin.
9 ) The method of claim 1 wherein the biodegradable layer comprises a lipid lowering agent.
10 ) The method of claim 1 wherein the biodegradable layer comprises a statin.